首页> 美国卫生研究院文献>Molecules >Discovery of Potential M2 Channel Inhibitors Based on the Amantadine Scaffold via Virtual Screening and Pharmacophore Modeling
【2h】

Discovery of Potential M2 Channel Inhibitors Based on the Amantadine Scaffold via Virtual Screening and Pharmacophore Modeling

机译:基于金刚烷胺骨架的虚拟筛选和药效团建模发现潜在的M2通道抑制剂

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The M2 channel protein on the influenza A virus membrane has become the main target of the anti-flu drugs amantadine and rimantadine. The structure of the M2 channel proteins of the H3N2 (PDB code 2RLF) and 2009-H1N1 (Genbank accession number ) viruses may help researchers to solve the drug-resistant problem of these two adamantane-based drugs and develop more powerful new drugs against influenza A virus. In the present study, we searched for new M2 channel inhibitors through a combination of different computational methodologies, including virtual screening with docking and pharmacophore modeling. Virtual screening was performed to calculate the free energies of binding between receptor M2 channel proteins and 200 new designed ligands. After that, pharmacophore analysis was used to identify the important M2 protein-inhibitor interactions and common features of top binding compounds with M2 channel proteins. Finally, the two most potential compounds were determined as novel leads to inhibit M2 channel proteins in both H3N2 and 2009-H1N1 influenza A virus.
机译:甲型流感病毒膜上的M2通道蛋白已成为抗流感药物金刚烷胺和金刚乙胺的主要靶标。 H3N2(PDB代码2RLF)和2009-H1N1(Genbank登录号)病毒M2通道蛋白的结构可能有助于研究人员解决这两种基于金刚烷的药物的耐药性问题,并开发出更强大的抗流感新药病毒。在本研究中,我们通过结合不同的计算方法(包括对接虚拟筛选和药效团建模)来寻找新的M2通道抑制剂。进行虚拟筛选以计算受体M2通道蛋白与200个新设计的配体之间结合的自由能。之后,使用药效基团分析来确定重要的M2蛋白-抑制剂相互作用和顶部结合化合物与M2通道蛋白的共同特征。最后,确定了两种最有潜力的化合物,作为抑制H3N2和2009-H1N1甲型流感病毒中M2通道蛋白的新线索。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号